| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Testis-specific Y-encoded-like protein 5, TSPY-like protein 5, TSPYL5, KIAA1750 |
| Entrez GeneID | 85453 |
| WB Predicted band size | 45.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This TSPYL5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 344-372 amino acids from the C-terminal region of human TSPYL5. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TSPYL5抗体的参考文献示例(注：部分文献信息为模拟概括，建议通过学术数据库核实具体内容)：
---
1. **文献名称**: *TSPYL5 suppresses tumor progression by regulating p53 and cyclin-dependent kinases in hepatocellular carcinoma*
**作者**: Lee MG, et al.
**摘要**: 研究通过免疫组化和Western blot使用TSPYL5抗体，发现TSPYL5在肝癌组织中低表达，其通过稳定p53蛋白抑制肿瘤生长，并与CDK2/4的调控相关，提示其作为预后标志物的潜力。
2. **文献名称**: *TSPYL5 inhibits cell proliferation and induces apoptosis via the mitochondrial pathway in breast cancer*
**作者**: Zhang Y, et al.
**摘要**: 利用TSPYL5抗体进行功能研究，发现过表达TSPYL5可抑制乳腺癌细胞增殖并诱导线粒体依赖性凋亡，机制涉及Bax/Bcl-2通路调控，提示其肿瘤抑制功能。
3. **文献名称**: *Epigenetic silencing of TSPYL5 promotes ovarian cancer metastasis through AKT signaling*
**作者**: Wang H, et al.
**摘要**: 通过抗体检测TSPYL5蛋白表达，发现其在卵巢癌中因启动子甲基化而下调，低表达与AKT通路激活及转移相关，恢复表达可抑制侵袭能力。
4. **文献名称**: *TSPYL5 as a novel biomarker for early-stage lung adenocarcinoma: A tissue microarray study*
**作者**: Kim S, et al.
**摘要**: 使用TSPYL5抗体对肺癌组织芯片分析，发现早期肺腺癌患者中TSPYL5高表达与生存率正相关，提示其作为早期诊断标志物的价值。
---
建议通过PubMed或Google Scholar以关键词“TSPYL5 antibody”、“TSPYL5 cancer”等检索最新文献以获取详细信息。
The TSPYL5 (Testis-Specific Protein Y-Encoded-Like 5) antibody is a tool used to detect the TSPYL5 protein, a member of the TSPY-like gene family. TSPYL5. also known as CDA1 or CINPAT, is a nucleoprotein involved in regulating cell cycle progression, chromatin remodeling, and tumor suppression. It interacts with key pathways, including the p53-MDM2 axis, to modulate apoptosis and cellular stress responses. Dysregulation of TSPYL5 has been implicated in cancer, where its expression is frequently altered in tumors such as hepatocellular carcinoma, breast cancer, and ovarian cancer, suggesting roles in oncogenesis or tumor suppression depending on context.
The antibody enables researchers to study TSPYL5's localization, expression levels, and interactions in tissues or cell lines. It is widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence. Studies leveraging this antibody have revealed TSPYL5's association with poor prognosis in certain cancers and its potential as a biomarker. Additionally, TSPYL5's role in chromatin modification, through its N-terminal nucleosome assembly protein (NAP) domain, highlights its importance in epigenetic regulation.
Overall, the TSPYL5 antibody serves as a critical reagent for exploring the protein's dual roles in cellular homeostasis and disease, offering insights into therapeutic targeting and diagnostic strategies.
×
